Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
ERASCA Aktie jetzt für 0€ handeln | |||||
02.06. | Erasca Announces Clearance Of IND Application By FDA For ERAS-4001 | - | RTTNews | ||
02.06. | FDA clears Erasca's new cancer drug applications | 1 | Investing.com | ||
13.05. | Erasca, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
13.05. | Erasca, Inc.: Erasca Reports First Quarter 2025 Business Updates and Financial Results | 48 | GlobeNewswire (Europe) | Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026... ► Artikel lesen | |
13.05. | Erasca, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
13.05. | Erasca enters another era, seeks partner for ph. 3 ex-Novartis asset | 1 | FierceBiotech | ||
13.05. | FDA clears Erasca's new cancer drug ERAS-0015 | 1 | Investing.com | ||
29.04. | Erasca, Inc.: Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
26.03. | Raymond James sets $5 target for Erasca stock, cites valuation gap | 5 | Investing.com | ||
25.03. | Erasca, Inc.: Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting | 1 | GlobeNewswire (USA) | ||
20.03. | Erasca GAAP EPS of -$0.11 beats by $0.02 | 3 | Seeking Alpha | ||
20.03. | Erasca, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
20.03. | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results | 496 | GlobeNewswire (Europe) | Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well... ► Artikel lesen | |
13.01. | Erasca, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
12.11.24 | Erasca, Inc.: Erasca Reports Third Quarter 2024 Business Updates and Financial Results | 497 | GlobeNewswire (Europe) | Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution... ► Artikel lesen | |
12.08.24 | Erasca, Inc.: Erasca Reports Second Quarter 2024 Business Updates and Financial Results | 187 | GlobeNewswire (Europe) | In-licensed potential best-in-class pan-RAS molecular glue ERAS-0015 and potential first-in-class pan-KRAS inhibitor ERAS-4001 with a goal of expanding treatment options across RAS-driven tumors Initiated... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CUREVAC | 4,560 | -0,91 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
MODERNA | 23,305 | +0,17 % | Laboratorios Rovi: FDA approves Moderna vaccine for RSV in adults aged 18 to 59 | ||
PAION | 0,011 | -27,03 % | Paion Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
ILLUMINA | 80,30 | -0,91 % | Code des Lebens entschlüsselt - so geht es weiter! Illumina, PanGenomic Health, Moderna | Erbinformationen sind die Baupläne des Lebens. Schon heute lassen sich mit Hilfe der Genomsequenzierung Informationen gewinnen, die unser Leben verlängern. Das gilt etwa, wenn wir bestimmte Vorprägungen... ► Artikel lesen | |
4SC | 0,648 | -0,31 % | PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten | DJ PTA-News: 4SC AG: Resminostat (Kinselby) negative Empfehlung des CHMP in der EU erhalten
Unternehmensmitteilung für den Kapitalmarkt
4SC AG: Resminostat (Kinselby) negative Empfehlung... ► Artikel lesen | |
NANOREPRO | 1,645 | -0,30 % | EQS-DD: NanoRepro AG: Dr. Olaf Stiller, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
26.05.2025 / 14:00... ► Artikel lesen | |
CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
REGENERON PHARMACEUTICALS | 444,00 | -0,22 % | Bayer, Regeneron get EU nod for Eylea's label extension | ||
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
OCUGEN | 0,858 | -1,06 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
INFLARX | 0,696 | -0,43 % | InflaRx N.V. - 6-K, Report of foreign issuer | ||
VIKING THERAPEUTICS | 22,700 | +0,13 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735 | VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes
SAN DIEGO, June 25, 2025 /PRNewswire/ -- Viking... ► Artikel lesen |